(MENAFN- PR Newswire) STARNBERG, Germany, March 24, 2021 /PRNewswire/ -- PARI Pharma GmbH, a company focused on advanced aerosol delivery systems based on eFlow Technology, announces the authorization ...
NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, reports that the Israeli Patent Office (ILPO) ...
SUN-101 (glycopyrrolate) is a long-acting muscarinic antagonist (LAMA) bronchodilator delivered via the innovative, proprietary eFlow nebulizer closed system. Developed by PARI Pharma, eFlow is a ...
- ARIKAYCE is the First and Only Therapy Specifically Indicated for the Treatment of Mycobacterium Avium Complex (MAC) Lung Disease in Adult Patients with Limited or No Alternative Treatment Options - ...
STARNBERG, Germany, June 7, 2016 /PRNewswire/ -- PARI Pharma, a company focused on the development of advanced aerosol therapies using eFlow Technology, announces that its proprietary closed eFlow ...
GOLDEN (Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer)-5 was a Phase 3, 48-week, randomized, open-label, active-controlled, parallel-group, multicenter safety trial designed to ...
RICHMOND, Va., Jan. 26, 2015 /PRNewswire/ -- The eRapid Nebulizer System (eRapid) from PARI has been approved as the first electronic nebulizer by the Food and Drug Administration to deliver Genentech ...
MONTEREY, Calif., Oct. 6 Today, PARI Pharma GmbH willunveil a prototype Closed System using eFlow Technology that uses single doseampoules to control medication used in the nebulizer system. By ...
Sunovion Pharmaceuticals Inc. moved its nebulized long-acting muscarinic antagonist (LAMA) into phase III development by opening the final two studies in a pivotal program that will collectively ...
Cuireadh roinnt torthaí i bhfolach toisc go bhféadfadh siad a bheith dorochtana duit
Taispeáin torthaí dorochtana
Aiseolas